Article Listing - Strong data for Prezista HIV regimen

Bionor Pharma leaps on positive trial results of HIV vaccine Vacc-4x with Revlimid

14 June 2013

Norway-based Bionor Pharma (OSE: BIONOR) saw its shares leap 16% to 3.67 kroner on June 13, after the company revealed that the first part of its phase II clinical study combining the HIV vaccine, Vacc-4x, with Celgene's immunomodulator, Revlimid (lenalidomide), has been successfully completed.

NICE says "yes" to Alimera's Iluvien for treatment of diabetic macular edema

14 June 2013

In draft guidance published today (June 14) by UK drugs watch dog the National Institute for Health and Care Excellence (NICE) it is recommending US ophthalmic biopharma specialist Alimira Sciences (Nasdaq: ALIM) Iluvien (fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular edema considered insufficiently responsive to available therapies, reversing a prior draft guidance last summer (The Pharma Letter August 8, 2012).

Genetics and genomics industry in the USA has a trillion dollar impact, new Battelle study shows

14 June 2013

A new Battelle study released this week by United for Medical Research illustrates the genetics and genomics industry's impact on the US economy has reached nearly a trillion dollars. The study is based on new data collected over the previous two years, and represents an update to the highly-cited Battelle 2011 report tracking the growth of the industry and its links to the federally funded Human Genome Project (HGP).

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib

13 June 2013

Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech firm Celgene (Nasdaq: CELG) presented positive data from a third Phase III randomized controlled study, dubbed PALACE 3, of apremilast in psoriatic arthritis.

Turkey's NSCLC drug market forecast to expand at 7% a year through 2017

13 June 2013

From 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual rate of 7%, reaching a value of $73 million in 2017, according to a new report from health care advisory firm Decision Resources.

Sunesis Pharma's VALOR trial of vosaroxin should continue with no change, says DSMB

13 June 2013

Sunesis Pharmaceuticals (Nasdaq: SNSS) says that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed its latest periodic safety review and recommended that the trial continue as planned without changes to study conduct.

Sagent Pharma expands voluntary withdrawal of vecuronium inj vials

13 June 2013

US drugmaker Sagent Pharmaceuticals (Nasdaq: SGNT) said today (June 13) that it is expanding its voluntary nationwide recall of vecuronium bromide for injection 10mg (NDC number 25021-657-10) manufactured by Turkey-based Mustafa Nevzat Ilac Sanayii (MN Pharmaceuticals) and distributed by Sagent. This recall is being conducted with the knowledge of the US Food and Drug Administration.

Increased focus on generics and biosimilars only way to make European health care sustainable, says EGA

13 June 2013

Addressing delegates at the 19th European Generic medicines Association (EGA) Annual Conference in Athens, Greece, its president Gudbjorg Edda Eggertsdottir stressed that generic and biosimilar medicines companies ensuring high-quality manufacturing jobs and know-how should remain in Europe; benefiting society and patients and increasing the competitiveness and innovative capacity of this strategic industry.

Amgen's trebananib meets primary end-point in Ph III study of recurrent ovarian cancer

13 June 2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has announced that the Phase III TRINOVA-1 trial evaluating trebananib (AMG 386) plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS).

First approved new class of IBS-C therapy, Constella, now available in Europe

13 June 2013

Spain's largest drugmaker Almirall (ALM: MC) and US partner Ironwood Pharmaceuticals, (Nasdaq: IRWD) today (June 13) announced the launch of Constella (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C, in Europe. Constella is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.

Showing 41-50 of 95575 articles